Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

1134390

USP

Clarithromycin Identity

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Clarithromycin

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C38H69NO13
CAS Number:
81103-11-9
Molecular Weight:
747.95
MDL number:
MFCD00865140
UNSPSC Code:
41116107
PubChem Substance ID:
329749413
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

clarithromycin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O[C@@H]([C@@](O)(C)[C@@H](CC)OC([C@H](C)[C@H]1O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)=O)[C@@H](C)C([C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3O)[C@H]1C)=O

InChI

1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1

InChI key

AGOYDEPGAOXOCK-KCBOHYOISA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Clarithromycin Identity USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Clarithromycin
  • Clarithromycin Tablets
  • Clarithromycin Extended-Release Tablets

Biochem/physiol Actions

Clarithromycin is a macrolide antibiotic that interferes with bacterial protein synthesis. Clarithromycin is an acid-stable version of erythromycin and is particularly effective against Gram-negative bacteria. It has a short half-life, however its metabolite, 14-hydroxy clarithromycin is nearly twice as active as clarithromycin against certain bacteria.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1134379

Clarithromycin, United States Pharmacopeia (USP) Reference Standard

Y0000321

Clarithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0000320

Clarithromycin, European Pharmacopoeia (EP) Reference Standard

1134380

Clarithromycin Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR1038

Clarithromycin, Pharmaceutical Secondary Standard; Certified Reference Material

1134642

Clarithromycin Impurity R, United States Pharmacopeia (USP) Reference Standard

1134631

Clarithromycin Impurity Q, United States Pharmacopeia (USP) Reference Standard

1134619

Clarithromycin Impurity D, United States Pharmacopeia (USP) Reference Standard

1134620

Clarithromycin Impurity H, United States Pharmacopeia (USP) Reference Standard

BP834

Clarithromycin impurity E, British Pharmacopoeia (BP) Reference Standard

Regulatory Information

监管及禁止进口产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Keith A Rodvold et al.
Antimicrobial agents and chemotherapy, 47(8), 2450-2457 (2003-07-25)
The purpose of this study was to compare the concentrations of levofloxacin and azithromycin in steady-state plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) after intravenous administration. Thirty-six healthy, nonsmoking adult subjects were randomized to either intravenous levofloxacin (500
Chung-Su Park et al.
The American journal of gastroenterology, 109(10), 1595-1602 (2014-08-06)
Helicobacter pylori eradication rates with clarithromycin-based triple therapy are declining, and an alternative strategy is needed urgently. We sought to compare the efficacy of pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for H. pylori eradication in a region with high
Stig Lyngbæk et al.
European journal of preventive cardiology, 21(10), 1275-1284 (2013-06-01)
Low prevalence of detectable cardiac troponin in healthy people and low-risk patients previously curtailed its use. With a new high-sensitive cardiac troponin assay (hs-cTnT), concentrations below conventional detection may have prognostic value, notably in combination with N-terminal pro-B-type natriuretic peptide
Jerry M Zuckerman
Infectious disease clinics of North America, 18(3), 621-649 (2004-08-17)
The advanced macrolides, azithromycin and clarithromycin, and the ketolide telithromycin are structural analogues of erythromycin. They have several distinct advantages when compared with erythromycin including enhanced spectrum of activity, more favorable pharmacokinetics and pharmacodynamics, once daily administration, and improved tolerability.
Alicia C Marin et al.
Expert opinion on pharmacotherapy, 14(7), 843-861 (2013-03-30)
Helicobacter pylori infection is generally treated with therapies that include a proton pump inhibitor (PPI) and, at least, two antibiotics being clarithromycin one of the most used. Antibiotic resistance, mainly to clarithromycin, seems to be increasing in many geographical areas
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service